skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis

Canadian respiratory journal, 2020-10, Vol.2020, p.1-16 [Peer Reviewed Journal]

Copyright © 2020 Teshale Ayele Mega et al. ;COPYRIGHT 2020 Hindawi Limited ;Copyright © 2020 Teshale Ayele Mega et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0 ;Copyright © 2020 Teshale Ayele Mega et al. 2020 ;ISSN: 1198-2241 ;EISSN: 1916-7245 ;DOI: 10.1155/2020/4312519 ;PMID: 33082891

Full text available

Citations Cited by
  • Title:
    The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis
  • Author: Ayele Mega, Teshale ; Feyissa, Temesgen Mulugeta ; Dessalegn Bosho, Dula ; Kumela Goro, Kabaye ; Zeleke Negera, Getandale
  • Imai, Hisao ; Hisao Imai
  • Subjects: Bias ; Cardiovascular disease ; Clinical trials ; Coronaviruses ; COVID-19 ; Hospitalization ; Hydroxychloroquine ; Meta-analysis ; Mortality ; Patient outcomes ; Review ; Severe acute respiratory syndrome coronavirus 2 ; Systematic review
  • Is Part Of: Canadian respiratory journal, 2020-10, Vol.2020, p.1-16
  • Description: Background. The pandemic of coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in an unprecedented public health challenge worldwide. Despite urgent and extensive global efforts, the existing evidence is inconclusive regarding the medications used for the treatment of COVID-19. Purpose. To generate an up-to-date evidence for the clinical safety and efficacy of hydroxychloroquine (HCQ) with or without azithromycin (AZ) among patients treated for COVID-19. Data Source. PubMed, Cochrane CENTRAL, LITCOVID, Web of Science, SCOPUS, BioRxiv, Embase, MedRxiv, and Wiley online library were searched from 2019/12/30 to 2020/05/23. Study Selection. Three investigators assessed the quality of the studies. Data Extraction. Data about study characteristics, effect estimates, and the quality of the studies were extracted by two independent reviewers and cross-checked by the third reviewer. Data Synthesis. The data of 6,782 (HCQ group, 3623; HCQ + AZ group, 1,020; control group, 2139) participants were included. HCQ was compared with standard care for virologic efficacy, disease progression, mortality, and adverse effects. HCQ was also compared with HCQ + AZ for QTc prolongation, admission to the intensive care unit, and mortality. The study found HCQ did not alter the rate of virologic cure (OR = 0.78; 95% CI: 0.39–1.56) and the risk of mortality (OR = 1.26; 95% CI: 0.66–2.39). The pooled prevalence for mortality was 5.8% (95% CI: 0.9%–10.8%). Moreover, HCQ did not impact disease progression (OR = 0.9; 95% CI: 0.36–2.29) but resulted in a higher risk of adverse effects (OR = 2.35; 95% CI: 1.15–4.8). HCQ was also compared against HCQ + AZ, and no difference was observed in QTc prolongation above 500 ms (OR = 1.11; 95% CI: 0.54–2.28), admission to the intensive care unit (OR = 0.92; 95% CI: 0.52–1.63), and mortality (OR = 0.88; 95% CI: 0.55–1.43). However, in the analysis of single-arm studies, about 11.2% (95% CI: 7.0%–15.5%) of patients have developed an absolute increase of QTc greater than 500 ms, and 4.1% (95% CI: 1.1%–7.1%) of patients discontinued their medication. Conclusion. This meta-analysis and systematic review, which included a limited number of poorly designed studies of patients with COVID-19, revealed HCQ is intolerable, unsafe, and not efficacious. Similarly, HCQ + AZ combination was not different from HCQ alone in curbing mortality and ICU admission.
  • Publisher: Oakville: Hindawi
  • Language: English;French
  • Identifier: ISSN: 1198-2241
    EISSN: 1916-7245
    DOI: 10.1155/2020/4312519
    PMID: 33082891
  • Source: Geneva Foundation Free Medical Journals at publisher websites
    PubMed Central
    Coronavirus Research Database
    ProQuest Central
    DOAJ Directory of Open Access Journals
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait